Tuberculosis enzyme's dual LPS/LTA binding inspires a broad-spectrum antibacterial peptide
- Peptides were derived from the structure of M. tuberculosis adenylate kinase, which binds both LPS and LTA, to cover Gram-negative and Gram-positive bacteria.
- Non-natural residues, N-terminal C6 acylation and arginine extension gave lead YK-mAK-17, an amphipathic helix that disrupts membranes and virulence pathways.
- It was stable, showed little resistance development, and was active against CRAB and MRSA.
- In mouse septic shock models it improved survival and limited organ damage.
💡 Points Based on the abstract
Cationic amphipathic helices with lipid tails always look good on killing curves, so my first question is the therapeutic window: hemolysis, mammalian cytotoxicity and serum or plasma binding decide whether this beats polymyxin-type chemotypes. Membrane-disrupting mechanisms also blur LPS/LTA recognition with plain charge-driven lysis. I'd test a scrambled or less-charged control and look at how the acyl chain and arginine count move toxicity.